MedTrace Logo

Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis

NCT01029782 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2018-08-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether oral cephalexin is equivalent to intravenous cefazolin plus oral probenecid for the treatment of uncomplicated skin and soft tissue infections in patients that present to the emergency department.

Conditions

  • Cellulitis

Interventions

DRUG

IV cefazolin plus oral probenecid and placebo cephalexin

Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.

DRUG

Oral cephalexin and saline IV plus probenecid placebo

Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily

Sponsors & Collaborators

  • Canadian Society of Hospital Pharmacists

    collaborator OTHER

  • Capital Health, Canada

    collaborator OTHER

  • Interior Health Authority, Canada

    collaborator UNKNOWN

  • Kelowna General Hospital

    lead OTHER_GOV

Principal Investigators

  • Dawn Dalen, PharmD · Interior Health

  • Peter Zed, PharmD · Capital Health, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01029782 on ClinicalTrials.gov